LS1034 Xenograft Model Service for Colon Cancer

The LS1034 xenograft model represents a robust preclinical platform for colon cancer research, enabling precise evaluation of therapeutic efficacy in a physiologically relevant tumor microenvironment. At Alfa Cytology, we specialize in delivering validated LS1034 colon cancer xenograft models tailored to advance your preclinical drug development pipeline with reproducible data and expert technical support.

Overview of LS1034 Xenograft Model for Colon Cancer

The LS1034 cell line was established in 1992 from a primary tumor biopsy of the cecum in a 54-year-old Caucasian male patient diagnosed with Dukes' type C, moderately to poorly differentiated colorectal adenocarcinoma. As an epithelial cell line with confirmed tumorigenicity in immunodeficient mice, LS1034 has become a valuable preclinical model for studying colon cancer biology, therapeutic response, and tumor microenvironment interactions. The cell line exhibits a hyperdiploid karyotype with modal chromosome number of 77 and carries key oncogenic mutations including mutated p53 (Gly245Ser) and APC deletion, making it particularly relevant for investigating pathways implicated in colorectal carcinogenesis and drug resistance mechanisms.

In xenograft applications, LS1034 demonstrates reliable engraftment potential with reproducible tumor growth kinetics, providing researchers with a consistent platform for pharmacological studies. The model has been extensively utilized in investigations of CD44/CD133 cancer stem cell dynamics, combination therapy strategies targeting PI3K/MAPK pathways, and evaluations of novel chemotherapeutic agents. LS1034's multidrug-resistant phenotype and sensitivity to TGF-beta inhibition further enhance its utility for preclinical studies aimed at overcoming therapeutic resistance in colorectal cancer.

Figure 1. CRC cell lines show heterogeneous CD133/CD44 surface expression pattern not reflecting engraftment. (Dinger, Thiemo F., et al., 2020)

Cell Line Information: LS1034

The following table summarizes the comprehensive characteristics of the LS1034 cell line for preclinical research applications:

Our Services

Alfa Cytology leverages decades of collective expertise in preclinical oncology to provide fully characterized LS1034 xenograft models with stringent quality control, ensuring that every study generates reliable, publication-ready data for your drug discovery and development programs.

Workflow of LS1034 Xenograft Model Construction

Our standardized LS1034 xenograft model construction follows a rigorous multi-step protocol designed to ensure tumor engraftment consistency, reproducible growth kinetics, and reliable endpoint measurements for preclinical therapeutic evaluation.

1. Cell Line Authentication and Expansion: LS1034 cells are authenticated via STR profiling and confirmed mycoplasma-negative before expansion. Cells are cultured in RPMI-1640 supplemented with 10% FBS under standard conditions (37 degrees C, 5% CO2) and harvested at logarithmic growth phase for optimal viability.
2. Pre-Injection Cell Preparation: Cultured LS1034 cells are detached using trypsin-EDTA, washed with PBS, and resuspended in serum-free RPMI-1640 or Matrigel mixture at a concentration of 1-5 x 10^7 cells/mL. Cell viability is verified by trypan blue exclusion (>95% viability required).
3. Animal Preparation and Subcutaneous Injection: Immunodeficient nude mice (nu/nu) aged 6-8 weeks are acclimatized under pathogen-free conditions. LS1034 cell suspension (typically 100-200 µL containing 1-5 x 10^6 cells) is injected subcutaneously into the right flank using a sterile 25-gauge needle.
4. Tumor Monitoring and Measurement: Tumor growth is monitored twice weekly using digital caliper measurements. Tumor volume is calculated using the formula V = (L x W^2)/2, where L represents the longest diameter and W the perpendicular width. Mice are randomized into treatment groups when tumors reach 100-200 mm^3.
5. Therapeutic Intervention and Endpoint Analysis: Test compounds are administered according to predefined dosing schedules. Animals are monitored for body weight, tumor burden, and general health status. At study termination, tumors are excised, weighed, and processed for histopathological, biomarker, and molecular analyses.

Figure 2: Schematic workflow illustrating the derivation and construction of the LS1034 Xenograft Model at Alfa Cytology.

Case Study-LS1034 Xenograft Model Development

In a recent preclinical engagement, Alfa Cytology successfully established LS1034 subcutaneous xenografts with consistent engraftment rates and predictable tumor growth patterns suitable for combination therapy evaluation. The model demonstrated robust tumor take and measurable response to standard-of-care reference compounds, providing a reliable foundation for client-specific therapeutic candidate assessment. Detailed growth curves, pharmacodynamic biomarker data, and histopathological findings are available upon formal inquiry through our scientific team.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your LS1034 colon cancer xenograft studies ensures access to validated models, technical excellence, and comprehensive project support from study design to data delivery.

• Fully authenticated LS1034 cell lines with confirmed STR profiles and mycoplasma-free certification.
• Standardized xenograft protocols optimized for consistent tumor engraftment and reproducible growth kinetics.
• Experienced in vivo oncology team with expertise in combination therapy and biomarker-driven endpoint analysis.
• Flexible study designs accommodating single-agent, combination, and dose-escalation therapeutic strategies.
• Comprehensive data packages including tumor growth curves, body weight monitoring, and histopathological reporting.
• Dedicated project management ensuring transparent communication and adherence to predefined timelines.

Contact Us

Ready to advance your colon cancer preclinical program with our LS1034 xenograft model services? Contact us today to discuss your study requirements, obtain a customized proposal, or schedule a consultation with our scientific team. Reach out to us via email or through our website inquiry form, and let Alfa Cytology accelerate your path from discovery to development.

For research use only. Not intended for any clinical use.